Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Crossref DOI link: https://doi.org/10.1007/s11523-020-00762-6
Published Online: 2020-10-27
Published Print: 2020-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Eskens, Ferry
Blumenschein, George Jr.
Richards, Donald
Genvresse, Isabelle
Reschke, Susanne
Granvil, Camille
Skubala, Adam
Peña, Carol
Mross, Klaus
Text and Data Mining valid from 2020-10-27
Version of Record valid from 2020-10-27
Article History
First Online: 27 October 2020